InsiderSource
CRVS

Corvus Pharmaceuticals, Inc.

SEC CIK 1626971
$11.93 −42.7% · 90 days
90-day buys
$83.5K
2 open-market
90-day sells
$0
0 open-market
Net insider flow
+$83.5K
Net buying
Filings shown
66
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at CRVS have bought a net $83.5K of stock (2 open-market buys vs 0 sells).

Largest recent trade: Orbimed Advisors Llc sold $4.89M of CRVS, trimming their stake 14%.

Most active filer: Miller Richard A Md, with 38 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for CRVS, newest first
View on SEC EDGAR ↗
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 28, 2022 ΔOwn +0.4%

Miller Richard A Md, CRVS's CEO, spent $5.2K of their own money on 5,000 shares at $1.

+$5.2K
5,000 sh @ $1
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 6, 2022 ΔOwn +0.4%

Miller Richard A Md, CRVS's CEO, spent $4.7K of their own money on 4,830 shares at $1.

+$4.7K
4,830 sh @ $1
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Apr 1, 2022 ΔOwn +1.1%

Miller Richard A Md, CRVS's CEO, spent $24.5K of their own money on 15,000 shares at $2, growing their stake 1%.

+$24.5K
15,000 sh @ $2
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Mar 17, 2022 ΔOwn +0.4%

Miller Richard A Md, CRVS's CEO, spent $8K of their own money on 5,000 shares at $2.

+$8K
5,000 sh @ $2
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Mar 17, 2022 ΔOwn +1.9%

Miller Richard A Md, CRVS's CEO, spent $36.7K of their own money on 25,000 shares at $1, growing their stake 2%.

+$36.7K
25,000 sh @ $1
Advertisement
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Aug 23, 2021 ΔOwn +0.8%

Miller Richard A Md, CRVS's CEO, spent $19.3K of their own money on 10,000 shares at $2, growing their stake 1%.

+$19.3K
10,000 sh @ $2
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed May 5, 2021 ΔOwn NEW

Miller Richard A Md, CRVS's CEO, spent $100K of their own money on 35,714 shares at $3, opening a brand-new position.

+$100K
35,714 sh @ $3
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Feb 17, 2021 ΔOwn +8.5%

Miller Richard A Md, CRVS's CEO, spent $350K of their own money on 100,000 shares at $4, growing their stake 8%.

+$350K
100,000 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Nov 14, 2019 ΔOwn +1.3%

Miller Richard A Md, CRVS's CEO, spent $44.2K of their own money on 14,736 shares at $3, growing their stake 1%.

+$44.2K
14,736 sh @ $3
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Aug 8, 2019 ΔOwn +0.2%

Miller Richard A Md, CRVS's CEO, spent $8.9K of their own money on 2,500 shares at $4.

+$8.9K
2,500 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Aug 8, 2019 ΔOwn +0.4%

Miller Richard A Md, CRVS's CEO, spent $17.9K of their own money on 5,000 shares at $4.

+$17.9K
5,000 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 17, 2019 ΔOwn +1.0%

Miller Richard A Md, CRVS's CEO, spent $39.7K of their own money on 11,657 shares at $3, growing their stake 1%.

+$39.7K
11,657 sh @ $3
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 17, 2019

Miller Richard A Md, CRVS's CEO, spent $1.2K of their own money on 343 shares at $4.

+$1.2K
343 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 11, 2019 ΔOwn +0.5%

Miller Richard A Md, CRVS's CEO, spent $22K of their own money on 6,000 shares at $4, growing their stake 1%.

+$22K
6,000 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 11, 2019 ΔOwn +0.8%

Miller Richard A Md, CRVS's CEO, spent $31K of their own money on 9,212 shares at $3, growing their stake 1%.

+$31K
9,212 sh @ $3
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Dec 31, 2018 ΔOwn +1.8%

Miller Richard A Md, CRVS's CEO, spent $65.9K of their own money on 20,000 shares at $3, growing their stake 2%.

+$65.9K
20,000 sh @ $3
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Dec 26, 2018 ΔOwn +0.5%

Miller Richard A Md, CRVS's CEO, spent $22K of their own money on 5,000 shares at $4.

+$22K
5,000 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Dec 26, 2018 ΔOwn +0.5%

Miller Richard A Md, CRVS's CEO, spent $22K of their own money on 5,000 shares at $4.

+$22K
5,000 sh @ $4
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Dec 10, 2018 ΔOwn +0.4%

Miller Richard A Md, CRVS's CEO, spent $29.9K of their own money on 5,000 shares at $6.

+$29.9K
5,000 sh @ $6
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Dec 6, 2018 ΔOwn +0.1%

Miller Richard A Md, CRVS's CEO, spent $8.9K of their own money on 1,502 shares at $6.

+$8.9K
1,502 sh @ $6
CRVS
Corvus Pharmaceuticals, Inc.
Buy Gould Terry P · Director, 10% Owner · Open-market purchase · filed Mar 13, 2018 ΔOwn NEW

Gould Terry P, CRVS's 10% owner, spent $593.8K of their own money on 69,864 shares at $9, opening a brand-new position.

+$593.8K
69,864 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy Gould Terry P · Director, 10% Owner · Open-market purchase · filed Mar 13, 2018 ΔOwn NEW

Gould Terry P, CRVS's 10% owner, spent $2.01M of their own money on 236,128 shares at $9, opening a brand-new position.

+$2.01M
236,128 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy Gould Terry P · Director, 10% Owner · Open-market purchase · filed Mar 13, 2018 ΔOwn NEW

Gould Terry P, CRVS's 10% owner, spent $576K of their own money on 67,769 shares at $9, opening a brand-new position.

+$576K
67,769 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy Gould Terry P · Director, 10% Owner · Open-market purchase · filed Mar 13, 2018 ΔOwn NEW

Gould Terry P, CRVS's 10% owner, spent $745.2K of their own money on 87,668 shares at $9, opening a brand-new position.

+$745.2K
87,668 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy Gould Terry P · Director, 10% Owner · Open-market purchase · filed Mar 13, 2018 ΔOwn NEW

Gould Terry P, CRVS's 10% owner, spent $1.08M of their own money on 126,806 shares at $9, opening a brand-new position.

+$1.08M
126,806 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Mar 12, 2018 ΔOwn +9.9%

Miller Richard A Md, CRVS's CEO, spent $850K of their own money on 100,000 shares at $9, growing their stake 10%.

+$850K
100,000 sh @ $9
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Nov 22, 2017 ΔOwn +1.0%

Miller Richard A Md, CRVS's CEO, spent $107.9K of their own money on 10,000 shares at $11, growing their stake 1%.

+$107.9K
10,000 sh @ $11
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 13, 2017 ΔOwn +0.3%

Miller Richard A Md, CRVS's CEO, spent $24.4K of their own money on 2,500 shares at $10.

+$24.4K
2,500 sh @ $10
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 13, 2017 ΔOwn +0.3%

Miller Richard A Md, CRVS's CEO, spent $25.4K of their own money on 2,500 shares at $10.

+$25.4K
2,500 sh @ $10
CRVS
Corvus Pharmaceuticals, Inc.
Buy MILLER RICHARD A MD · Director, President and CEO · Open-market purchase · filed Jun 13, 2017 ΔOwn +1.1%

Miller Richard A Md, CRVS's CEO, spent $110.2K of their own money on 11,216 shares at $10, growing their stake 1%.

+$110.2K
11,216 sh @ $10
Advertisement

About CRVS insider activity

This page tracks every recent Form 4 filed for Corvus Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

What are the latest CRVS insider transactions?

The most recent Form 4 filings for CRVS are listed at the top of this page, newest first, usually within minutes of SEC acceptance. Each row shows the insider, transaction code, share count, and dollar value.

How often is CRVS insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Corvus Pharmaceuticals, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.